Previous close | 0.3989 |
Open | 0.3970 |
Bid | 0.5500 x 2200 |
Ask | 0.5799 x 2900 |
Day's range | 0.3857 - 0.3970 |
52-week range | 0.3700 - 1.5000 |
Volume | |
Avg. volume | 72,970 |
Market cap | 22.037M |
Beta (5Y monthly) | 0.35 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.7700 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Movano Health (Nasdaq: MOVE), a pioneer in health technology, has completed another hypoxia trial with the University of California, San Francisco (UCSF) yielding new blood oxygen saturation (SpO2) data, confirming the accuracy of its Evie Ring pulse oximeter exceeds the U.S. Food and Drug Administration (FDA) guidelines.
Movano Health (Nasdaq: MOVE), a pioneer in health technology, announced that its female first wearable, the Evie Ring, will begin shipping today.
Movano Health (Nasdaq: MOVE), a pioneer in health technology, and ams OSRAM, a leader in technology for biometric monitoring, have collaborated to include ams OSRAMs PPG sensor solution in the Evie Ring, Movano Health's smart ring designed specifically for women.